|
The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday. ---------- SMALL-CAP - WINNERS ---------- Carr’s Group PLC, up 4.4% at 140.88 pence, 12-month range 101.5p-157p. The Carlisle, England-based agriculture products company says its partnership with Seales Winslow ‘has proved successful, with operational transition and customer migration benefits ahead of schedule’ since Seales became the group’s New Zealand third-party distributor in November 2024. Carr’s closed its New Zealand business in 2024 but says the country remains a meaningful extensive livestock market, saying ‘its robust dairy, beef and sheep sectors continue to drive strong demand for high-quality mineral supplementation solutions’. Adds that both companies expect to achieve further benefits as the distribution deal enters its second year. ---------- Zotefoams PLC, up 2.9% at 431.25p, 12-month range 225p-470p. The supercritical foams company promotes Simon Corner to chief strategy & innovation officer, ‘expanding on his previous role as group strategy & delivery director’. Company also announces plans to create a Global Innovation Hub in the UK, and a Footwear Innovation Centre in South Korea, investing £6.8 million over the next three years of which £4.5 million will go towards the UK facility. Says the investment is reflected in its existing market guidance, and will strengthen its competitive positioning and advance its growth strategy. ‘Our Global Innovation Hub will serve as the worldwide engine for breakthrough technologies, while our Footwear Innovation Centre in South Korea places us at the heart of one of the world’s most dynamic athletic footwear markets,’ comments Chief Executive Ronan Cox. ---------- SMALL-CAP - LOSERS ---------- PureTech Health PLC, down 5.2% at 127.00p, 12-month range 103p-173.6p. The Boston, Massachusetts-based biotech and pharmaceutical firm’s net loss has narrowed to $43.9 million in the six months to June 30 from $55.0 million the previous year. Revenue increases to $1.9 million from $288,000, which PureTech says is primarily due to the recognition of royalty revenue from sales of Cobenfy. Reports lower costs, which it says are primarily driven by workforce reductions. General & administrative expenses drop 10% to $24.9 million, and research and development expenses are reduced 36% to $24.9 million. Company says it is committed to ‘advancing our current portfolio efficiently, maintaining a strong balance sheet, and taking a disciplined approach to new innovation’. Expects ‘operational support’ for Celea and Gallop to significantly reduce cash burn over the course of 2026, while preserving potential upside. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
